GSK press releases Follow GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older In the EU, an average of 158,000 adults are hospitalised with RSV-related illness every year https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-receives-european-approval-for-expanded-use-in-all-adults-18-years-and-older/ gsk.com
